


**AMENDMENTS TO THE CLAIMS**

1. (Original) A compound according to formula I



wherein

X<sub>3</sub> and X<sub>4</sub> are selected from N and C, such that when X<sub>3</sub> is N, X<sub>4</sub> is C and when X<sub>3</sub> is C, X<sub>4</sub> is N;

P is selected from aryl and heteroaryl;

if m = 1 then R<sup>1</sup> is attached to P via a carbon atom on ring P at the meta-position of the ring P relative to the attachment point of P at X<sup>3</sup>, and if m = 2 then R<sup>1</sup> is attached to P via carbon atoms on ring P at the 2-, and 5-positions of the ring P;

R<sup>1</sup> is selected from the group consisting of hydroxy, halo, nitro, C<sub>1-6</sub>alkylhalo, OC<sub>1-6</sub>alkylhalo, C<sub>1-6</sub>alkyl, OC<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, OC<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, OC<sub>2-6</sub>alkynyl, C<sub>0-6</sub>alkylC<sub>3-6</sub>cycloalkyl, OC<sub>0-6</sub>alkylC<sub>3-6</sub>cycloalkyl, C<sub>0-6</sub>alkylaryl, OC<sub>0-6</sub>alkylaryl, CHO, (CO)R<sup>5</sup>, O(CO)R<sup>5</sup>, O(CO)OR<sup>5</sup>, O(CNR<sup>5</sup>)OR<sup>5</sup>, C<sub>1-6</sub>alkylOR<sup>5</sup>, OC<sub>2-6</sub>alkylOR<sup>5</sup>, C<sub>1-6</sub>alkyl(CO)R<sup>5</sup>, OC<sub>1-6</sub>alkyl(CO)R<sup>5</sup>, C<sub>0-6</sub>alkylCO<sub>2</sub>R<sup>5</sup>, OC<sub>1-6</sub>alkylCO<sub>2</sub>R<sup>5</sup>, C<sub>0-6</sub>alkylcyano, OC<sub>2-6</sub>alkylcyano, C<sub>0-6</sub>alkylNR<sup>5</sup>R<sup>6</sup>, OC<sub>2-</sub>

$\text{C}_6\text{alkylNR}^5\text{R}^6$ ,  $\text{C}_{1-6}\text{alkyl}(\text{CO})\text{NR}^5\text{R}^6$ ,  $\text{OC}_{1-6}\text{alkyl}(\text{CO})\text{NR}^5\text{R}^6$ ,  $\text{C}_{0-6}\text{alkylNR}^5(\text{CO})\text{R}^6$ ,  $\text{OC}_2\text{-}$   
 $\text{C}_6\text{alkylNR}^5(\text{CO})\text{R}^6$ ,  $\text{C}_{0-6}\text{alkylNR}^5(\text{CO})\text{NR}^5\text{R}^6$ ,  $\text{C}_{0-6}\text{alkylSR}^5$ ,  $\text{OC}_{2-6}\text{alkylSR}^5$ ,  $\text{C}_{0-6}\text{alkyl}(\text{SO})\text{R}^5$ ,  $\text{OC}_2\text{-}$   
 $\text{C}_6\text{alkyl}(\text{SO})\text{R}^5$ ,  $\text{C}_{0-6}\text{alkylSO}_2\text{R}^5$ ,  $\text{OC}_{2-6}\text{alkylSO}_2\text{R}^5$ ,  $\text{C}_{0-6}\text{alkyl}(\text{SO}_2)\text{NR}^5\text{R}^6$ ,  $\text{OC}_2\text{-}$   
 $\text{C}_6\text{alkyl}(\text{SO}_2)\text{NR}^5\text{R}^6$ ,  $\text{C}_{0-6}\text{alkylNR}^5(\text{SO}_2)\text{R}^6$ ,  $\text{OC}_{2-6}\text{alkylNR}^5(\text{SO}_2)\text{R}^6$ ,  $\text{C}_{0-6}\text{alkylNR}^5(\text{SO}_2)\text{NR}^5\text{R}^6$ ,  $\text{OC}_2\text{-}$   
 $\text{C}_6\text{alkylNR}^5(\text{SO}_2)\text{NR}^5\text{R}^6$ ,  $(\text{CO})\text{NR}^5\text{R}^6$ ,  $\text{O}(\text{CO})\text{NR}^5\text{R}^6$ ,  $\text{NR}^5\text{OR}^6$ ,  $\text{C}_{0-6}\text{alkylNR}^5(\text{CO})\text{OR}^6$ ,  $\text{OC}_2\text{-}$   
 $\text{C}_6\text{alkylNR}^5(\text{CO})\text{OR}^6$ ,  $\text{SO}_3\text{R}^5$  and a 5- or 6-membered ring containing one or more atoms  
independently selected from the group consisting of C, N, O and S;

$\text{X}^1$  is selected from the group consisting of  $\text{C}_{2-3}\text{alkyl}$ ,  $\text{C}_{2-3}\text{alkenyl}$ ,  $\text{NR}^3$ , O, S,  $\text{CR}^3\text{R}^4$ , SO,  $\text{SO}_2$

$\text{X}^2$  is selected from the group consisting of a bond,  $\text{CR}^3\text{R}^4$ , O, S,  $\text{NR}^3$ , SO,  $\text{SO}_2$

$\text{R}^3$  and  $\text{R}^4$  are independently selected from a group consisting of hydrogen, hydroxy,  $\text{C}_{1-6}\text{alkyl}$ ,  
 $\text{C}_{0-6}\text{alkylcyano}$ , oxo,  $=\text{NR}^5$ ,  $=\text{NOR}^5$ ,  $\text{C}_{1-4}\text{alkylhalo}$ , halo,  $\text{C}_{1-4}\text{alkylC}_{3-7}\text{cycloalkyl}$ ,  $\text{C}_{3-7}\text{cycloalkyl}$ ,  
 $\text{O}(\text{CO})\text{C}_{1-4}\text{alkyl}$ ,  $(\text{CO})\text{C}_{1-4}\text{alkyl}$ ,  $\text{C}_{1-4}\text{alkyl}(\text{SO})\text{C}_{0-4}\text{alkyl}$ ,  $\text{C}_{1-4}\text{alkyl}(\text{SO}_2)\text{C}_{0-4}\text{alkyl}$ ,  $(\text{SO})\text{C}_{0-4}\text{alkyl}$ ,  
 $(\text{SO}_2)\text{C}_{0-4}\text{alkyl}$ ,  $\text{OC}_{1-4}\text{alkyl}$ ,  $\text{C}_{1-4}\text{alkylOR}^5$  and  $\text{C}_{0-4}\text{alkylNR}^5\text{R}^6$ ;

Q is either selected from triazole, piperazine, and imidazole, or else Q is any other 4-, 5-, 6-, or  
7-membered heterocyclic ring containing one or more heteroatoms selected from N, O and S and  
is fused to a triazole ring;

$R^2$  is selected from the group consisting of hydroxy,  $C_{0-6}$ alkylcyano,  $=NR^5$ ,  $=O$ ,  $=NOR^5$ ,  $C_{1-4}$ alkylhalo, halo,  $C_{1-6}$ alkyl,  $C_{3-6}$ cycloalkyl,  $C_{0-6}$ alkylaryl,  $C_{0-6}$ alkylheteroaryl,  $C_{0-6}$ alkylcycloalkyl,  $C_{0-6}$ alkylheterocycloalkyl,  $OC_{1-4}$ alkyl,  $OC_{0-6}$ alkylaryl,  $O(CO)C_{1-4}$ alkyl,  $(CO)OC_{1-4}$ alkyl,  $C_{0-4}$ alkyl(S) $C_{0-4}$ alkyl,  $C_{1-4}$ alkyl(SO) $C_{0-4}$ alkyl,  $C_{1-4}$ alkyl(SO<sub>2</sub>) $C_{0-4}$ alkyl, (SO) $C_{0-4}$ alkyl, (SO<sub>2</sub>) $C_{0-4}$ alkyl,  $C_{1-4}$ alkylOR<sup>5</sup>,  $C_{0-4}$ alkylNR<sup>5</sup>R<sup>6</sup> and a 5- or 6-membered ring containing one or more atoms independently selected from C, N, O and S, which ring may optionally be fused with a 5- or 6-membered ring containing one or more atoms independently selected from the group consisting of C, N and O and wherein said ring and said fused ring may be substituted by one or more A; and

any  $C_{1-6}$ alkyl, aryl, or heteroaryl defined under  $R^1$ ,  $R^2$  and  $R^3$  may be substituted by one or more A; and

A is selected from the group consisting of hydrogen, hydroxy, halo, nitro, oxo,  $C_{0-6}$ alkylcyano,  $C_{0-4}$ alkyl $C_{3-6}$ cycloalkyl,  $C_{1-6}$ alkyl,  $-OC_{1-6}$ alkyl,  $C_{1-6}$ alkylhalo,  $OC_{1-6}$ alkylhalo,  $C_{2-6}$ alkenyl,  $C_{0-3}$ alkylaryl,  $C_{0-6}$ alkylOR<sup>5</sup>,  $OC_{2-6}$ alkylOR<sup>5</sup>,  $C_{1-6}$ alkylSR<sup>5</sup>,  $OC_{2-6}$ alkylSR<sup>5</sup>, (CO)R<sup>5</sup>, O(CO)R<sup>5</sup>,  $OC_{2-6}$ alkylcyano,  $OC_{1-6}$ alkylCO<sub>2</sub>R<sup>5</sup>, O(CO)OR<sup>5</sup>,  $OC_{1-6}$ alkyl(CO)R<sup>5</sup>,  $C_{1-6}$ alkyl(CO)R<sup>5</sup>, NR<sup>5</sup>OR<sup>6</sup>,  $C_{0-6}$ NR<sup>5</sup>R<sup>6</sup>,  $OC_{2-6}$ alkylNR<sup>5</sup>R<sup>6</sup>,  $C_{0-6}$ alkyl(CO)NR<sup>5</sup>R<sup>6</sup>,  $OC_{1-6}$ alkyl(CO)NR<sup>5</sup>R<sup>6</sup>,  $OC_{2-6}$ alkylNR<sup>5</sup>(CO)R<sup>6</sup>,  $C_{0-6}$ alkylNR<sup>5</sup>(CO)R<sup>6</sup>,  $C_{0-6}$ alkylNR<sup>5</sup>(CO)NR<sup>5</sup>R<sup>6</sup>, O(CO)NR<sup>5</sup>R<sup>6</sup>,  $C_{0-6}$ alkyl(SO<sub>2</sub>)NR<sup>5</sup>R<sup>6</sup>,  $OC_{2-6}$ alkyl(SO<sub>2</sub>)NR<sup>5</sup>R<sup>6</sup>,  $C_{0-6}$ alkylNR<sup>5</sup>(SO<sub>2</sub>)R<sup>6</sup>,  $OC_{2-6}$ alkylNR<sup>5</sup>(SO<sub>2</sub>)R<sup>6</sup>, SO<sub>3</sub>R<sup>5</sup>,  $C_{1-6}$ alkylNR<sup>5</sup>(SO<sub>2</sub>)NR<sup>5</sup>R<sup>6</sup>,  $OC_{2-6}$ alkyl(SO<sub>2</sub>)R<sup>5</sup>,  $C_{0-6}$ alkyl(SO<sub>2</sub>)R<sup>5</sup>,  $C_{0-6}$ alkyl(SO)R<sup>5</sup>,  $OC_{2-6}$ alkyl(SO)R<sup>5</sup> and a 5- or 6-membered ring containing one or more atoms independently selected from the group consisting of C, N, O and S;

$R^5$  and  $R^6$  are independently selected from, H,  $C_{1-6}$ alkyl,  $C_{3-7}$ cycloalkyl and aryl  
and salts and hydrates thereof

**m is selected from 1 or 2**

**p is selected from 0, 1, 2, 3 or 4**

**or a salt or hydrate thereof;**

**provided that the compound is not**

1-(2-benzothiazolyl)-4-[[5-(5-methyl-2-furanyl)-2H-tetrazol-2-yl]acetyl-piperazine,

1-(4-acetylphenyl)-4-[[5-(5-methyl-2-furanyl)-2H-tetrazol-2-yl]acetyl]-piperazine, or

5-(5-methyl-2-furanyl)-N-(2-phenyl-2H-benzotriazol-5-yl)-2H-tetrazole-2-acetamide.

2. (Original) A compound according to claim 1 wherein  $X_3$  is N and  $X_4$  is C.
3. (Original) A compound according to claim 1 wherein P is aryl.
4. (Original) A compound according to claim 3 wherein P is phenyl.
5. (Original) A compound according to claim 1 wherein  $R^1$  is selected from halo,  $C_{1-6}$ alkyl,  
-OC<sub>1-6</sub>alkyl, C<sub>0-6</sub>alkylcyano.

6. (Original) A compound according to claim 5 wherein,  $R^1$  is selected from Cl, F, cyano and methyl.
7. (Original) A compound according to claim 1 wherein  $X^1$  is  $CR^3R^4$ .
8. (Original) A compound according to claim 7 wherein  $X^2$  is selected from  $CR^3R^4$ , O, S and  $NR^3$ .
9. (Original) A compound according to claim 1 wherein Q is either selected from triazole and piperazine, or else Q is any other 4-, 5-, 6-, or 7-membered heterocyclic ring containing one or more heteroatoms selected from N, O and S and is fused to a triazole ring.
10. (Original) A compound according to claim 1 wherein Q is triazole.
11. (Original) A compound according to claim 1 wherein  $X^2$  is a bond.
12. (Original) A compound according to claim 1 wherein Q is piperazine.
13. (Original) A compound according to claim 1 wherein Q is a 5-, 6-, or 7-membered heterocyclic ring, other than triazole or piperazine, and is fused to a triazole ring.

14. (Original) A compound according to claim 1 wherein  $R^2$  is selected from the group consisting of  $C_{1-6}$ alkyl,  $C_{1-6}$ alkylhalo,  $C_{3-7}$ cylcoalkyl,  $C_{0-6}$ alkylaryl,  $C_{0-6}$ alkylheteroaryl,  $O(CO)C_{1-4}$ alkyl.
15. (Original) A compound according to claim 1 wherein  $R^2$  is a 5- or 6-membered ring containing one or more atoms independently selected from C, N, O and S, which ring may optionally be fused with a 5- or 6-membered ring containing one or more atoms independently selected from the group consisting of C, N and O and wherein said ring and said fused ring may be substituted by one or more A.
16. (Original) A compound according to claim 1 wherein A is selected from the group consisting of halo,  $-OC_{1-6}$ alkyl,  $C_{0-6}NR^5R^6$ ,  $C_{1-6}$ alkylhalo.
17. (Original) A compound according to claim 1 selected from:  
Ethyl 4- {[2-(3-chlorophenyl)-2H-tetrazol-5-yl]methyl}piperazine-1-carboxylate,  
4-[2-(5-Chloro-2-fluoro-phenyl)-2H-tetrazol-5-ylmethyl]-piperazine-1-carboxylic acid ethyl ester,  
4-(2-m-Tolyl-2H-tetrazol-5-ylmethyl)-piperazine-1-carboxylic acid ethyl ester,  
4-[2-(3-Iodo-phenyl)-2H-tetrazol-5-ylmethyl]-piperazine-1-carboxylic acid ethyl ester,  
4-[2-(3-Cyano-phenyl)-2H-tetrazol-5-ylmethyl]-piperazine-1-carboxylic acid ethyl ester,

4-[2-(2-Fluoro-5-methyl-phenyl)-2H-tetrazol-5-ylmethyl]-piperazine-1-carboxylic acid ethyl ester,

4-[5-([2-(3-chlorophenyl)-2H-tetrazol-5-yl]methyl)thio]-4-cyclopropyl-4H-1,2,4-triazol-3-yl] pyridine,

4-[5-([1-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]ethyl]thio)-4-cyclopropyl-4H-1,2,4-triazol-3-yl]pyridine,

Ethyl 4-{1-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]ethyl}piperazine-1-carboxylate,

4-{5-[2-(5-Chloro-2-fluoro-phenyl)-2H-tetrazol-5-ylmethylsulfanyl]-4-methyl-4H-[1,2,4]triazol-3-yl}-pyridine,

4-{5-[2-(5-Chloro-2-fluoro-phenyl)-2H-tetrazol-5-ylmethylsulfanyl]-4-cyclopropyl-4H-[1,2,4]triazol-3-yl}-pyridine,

4-(5-{1-[2-(5-Chloro-2-fluoro-phenyl)-2H-tetrazol-5-yl]-ethylsulfanyl}-4-methyl-4H-[1,2,4]triazol-3-yl)-pyridine,

4-(5-{1-[2-(5-Chloro-2-fluoro-phenyl)-2H-tetrazol-5-yl]-ethylsulfanyl}-4-cyclopropyl-4H-[1,2,4]triazol-3-yl)-pyridine,

4-{1-[2-(5-Chloro-2-fluoro-phenyl)-2H-tetrazol-5-yl]-ethyl}-piperazine-1-carboxylic acid ethyl ester,

4-[4-Cyclopropyl-5-(2-m-tolyl-2H-tetrazol-5-ylmethylsulfanyl)-4H-[1,2,4]triazol-3-yl]-pyridine,

4-{4-Cyclopropyl-5-[1-(2-m-tolyl-2H-tetrazol-5-yl)-ethylsulfanyl]-4H-[1,2,4]triazol-3-yl}-pyridine,

4-{4-Methyl-5-[1-(2-m-tolyl-2H-tetrazol-5-yl)-ethylsulfanyl]-4H-[1,2,4]triazol-3-yl}-pyridine,

3-[5-(4-Cyclopropyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-ylsulfanylmethyl)-tetrazol-2-yl]-benzonitrile,

3-{5-[1-(4-Cyclopropyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-ylsulfanyl)-ethyl]-tetrazol-2-yl}-benzonitrile

3-{5-[1-(4-Methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-ylsulfanyl)-ethyl]-tetrazol-2-yl}-benzonitrile  
4-{4-Cyclopropyl-5-[2-(2-fluoro-5-methyl-phenyl)-2H-tetrazol-5-ylmethylsulfanyl]-4H-[1,2,4]triazol-3-yl}-pyridine,

4-(4-Cyclopropyl-5-{1-[2-(2-fluoro-5-methyl-phenyl)-2H-tetrazol-5-yl]-ethylsulfanyl}-4H-[1,2,4]triazol-3-yl)-pyridine,

4-(5-{1-[2-(2-Fluoro-5-methyl-phenyl)-2H-tetrazol-5-yl]-ethylsulfanyl}-4-methyl-4H-[1,2,4]triazol-3-yl)-pyridine,

Methyl-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-(2-m-tolyl-2H-tetrazol-5-ylmethyl)-amine,

Methyl-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-[1-(2-m-tolyl-2H-tetrazol-5-yl)-ethyl]-amine,



[2-(3-Chloro-phenyl)-2H-tetrazol-5-ylmethyl]-methyl-(4-methyl-5-pyridin-4-yl-4H-

[1,2,4]triazol-3-yl)-amine,

{1-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-ethyl}-methyl-(4-methyl-5-pyridin-4-yl-4H-

[1,2,4]triazol-3-yl)-amine,

[2-(2-Fluoro-5-methyl-phenyl)-2H-tetrazol-5-ylmethyl]-methyl-(4-methyl-5-pyridin-4-yl-

4H-[1,2,4]triazol-3-yl)-amine,

{1-[2-(2-Fluoro-5-methyl-phenyl)-2H-tetrazol-5-yl]-ethyl}-methyl-(4-methyl-5-pyridin-4-yl-

4H-[1,2,4]triazol-3-yl)-amine,

[2-(3-Iodo-phenyl)-2H-tetrazol-5-ylmethyl]-methyl-(4-methyl-5-pyridin-4-yl-4H-

[1,2,4]triazol-3-yl)-amine,

{1-[2-(3-Iodo-phenyl)-2H-tetrazol-5-yl]-ethyl}-methyl-(4-methyl-5-pyridin-4-yl-4H-

[1,2,4]triazol-3-yl)-amine,

Methyl-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-(2-m-tolyl-2H-tetrazol-5-ylmethyl)-  
amine,

Methyl-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-[1-(2-m-tolyl-2H-tetrazol-5-yl)-  
ethyl]-amine,

[2-(3-Chloro-phenyl)-2H-tetrazol-5-ylmethyl]-methyl-(4-methyl-5-pyridin-4-yl-4H-

[1,2,4]triazol-3-yl)-amine,

{1-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-ethyl}-methyl-(4-methyl-5-pyridin-4-yl-4H-

[1,2,4]triazol-3-yl)-amine,

[2-(2-Fluoro-5-methyl-phenyl)-2H-tetrazol-5-ylmethyl]-methyl-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-amine,

{1-[2-(2-Fluoro-5-methyl-phenyl)-2H-tetrazol-5-yl]-ethyl}-methyl-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-amine,

8-[2-(3-Iodo-phenyl)-2H-tetrazol-5-ylmethyl]-3-pyridin-4-yl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine,

8-{1-[2-(3-Iodo-phenyl)-2H-tetrazol-5-yl]-ethyl}-3-pyridin-4-yl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine,

3-Pyridin-4-yl-8-(2-m-tolyl-2H-tetrazol-5-ylmethyl)-5,6,7,8-tetrahydro-4H-1,2,3a,8-tetraaza-azulene,

3-Pyridin-4-yl-8-[1-(2-m-tolyl-2H-tetrazol-5-yl)-ethyl]-5,6,7,8-tetrahydro-4H-1,2,3a,8-tetraaza-azulene,

8-[2-(3-Chloro-phenyl)-2H-tetrazol-5-ylmethyl]-3-pyridin-4-yl-5,6,7,8-tetrahydro-4H-1,2,3a,8-tetraaza-azulene,

8-{1-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-ethyl}-3-pyridin-4-yl-5,6,7,8-tetrahydro-4H-1,2,3a,8-tetraaza-azulene,

8-[2-(2-Fluoro-5-methyl-phenyl)-2H-tetrazol-5-ylmethyl]-3-pyridin-4-yl-5,6,7,8-tetrahydro-4H-1,2,3a,8-tetraaza-azulene,

8-{1-[2-(2-Fluoro-5-methyl-phenyl)-2H-tetrazol-5-yl]-ethyl}-3-pyridin-4-yl-5,6,7,8-tetrahydro-4H-1,2,3a,8-tetraaza-azulene,

8-[2-(3-Iodo-phenyl)-2H-tetrazol-5-ylmethyl]-3-pyridin-4-yl-5,6,7,8-tetrahydro-4H-1,2,3a,8-tetraaza-azulene,

8-{1-[2-(3-Iodo-phenyl)-2H-tetrazol-5-yl]-ethyl}-3-pyridin-4-yl-5,6,7,8-tetrahydro-4H-1,2,3a,8-tetraaza-azulene,

4-(5-{[2-(3-chlorophenyl)-2H-tetrazol-5-yl]methoxy}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine,

4-(5-{1-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine,

4-[4-Methyl-5-(2-m-tolyl-2H-tetrazol-5-ylmethoxy)-4H-[1,2,4]triazol-3-yl]-pyridine,

4-{4-Methyl-5-[1-(2-m-tolyl-2H-tetrazol-5-yl)-ethoxy]-4H-[1,2,4]triazol-3-yl}-pyridine,

4-{5-[2-(2-Fluoro-5-methyl-phenyl)-2H-tetrazol-5-ylmethoxy]-4-methyl-4H-[1,2,4]triazol-3-yl}-pyridine,

4-(5-{1-[2-(2-Fluoro-5-methyl-phenyl)-2H-tetrazol-5-yl]-ethoxy}-4-methyl-4H-[1,2,4]triazol-3-yl)-pyridine,

4-{5-[2-(3-Chloro-phenyl)-2H-tetrazol-5-ylmethoxy]-4-cyclopropyl-4H-[1,2,4]triazol-3-yl}-pyridine,

4-(5-{1-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-ethoxy}-4-cyclopropyl-4H-[1,2,4]triazol-3-yl)-pyridine,

4-[4-Cyclopropyl-5-(2-m-tolyl-2H-tetrazol-5-ylmethoxy)-4H-[1,2,4]triazol-3-yl]-pyridine,

4-{4-Cyclopropyl-5-[1-(2-m-tolyl-2H-tetrazol-5-yl)-ethoxy]-4H-[1,2,4]triazol-3-yl}-pyridine,

4-{4-Cyclopropyl-5-[2-(2-fluoro-5-methyl-phenyl)-2H-tetrazol-5-ylmethoxy]-4H-[1,2,4]triazol-3-yl}-pyridine,

4-(4-Cyclopropyl-5-{1-[2-(2-fluoro-5-methyl-phenyl)-2H-tetrazol-5-yl]-ethoxy}-4H-[1,2,4]triazol-3-yl)-pyridine,

4-{5-[2-(3-Iodo-phenyl)-2H-tetrazol-5-ylmethoxy]-4-methyl-4H-[1,2,4]triazol-3-yl}-pyridine,

4-(5-{1-[2-(3-Iodo-phenyl)-2H-tetrazol-5-yl]-ethoxy}-4-methyl-4H-[1,2,4]triazol-3-yl)-pyridine,

4-{4-Cyclopropyl-5-[2-(3-iodo-phenyl)-2H-tetrazol-5-ylmethoxy]-4H-[1,2,4]triazol-3-yl}-pyridine,

4-(4-Cyclopropyl-5-{1-[2-(3-iodo-phenyl)-2H-tetrazol-5-yl]-ethoxy}-4H-[1,2,4]triazol-3-yl)-pyridine,

3-[5-(4-Methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yloxymethyl)-tetrazol-2-yl]-benzonitrile

3-{5-[1-(4-Methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yloxy)-ethyl]-tetrazol-2-yl}-benzonitrile,

3-[5-(4-Cyclopropyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yloxymethyl)-tetrazol-2-yl]-benzonitrile,

3-{5-[1-(4-Cyclopropyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yloxy)-ethyl]-tetrazol-2-yl}-benzonitrile,

3-(5-{[Methyl-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-amino]-methyl}-tetrazol-2-yl)-benzonitrile,

3-(5-{1-[Methyl-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-amino]-ethyl}-tetrazol-2-yl)-benzonitrile,

3-[5-(3-Pyridin-4-yl-6,7-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrimidin-8-ylmethyl)-tetrazol-2-yl]-benzonitrile,

3-{5-[1-(3-Pyridin-4-yl-6,7-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrimidin-8-yl)-ethyl]-tetrazol-2-yl}-benzonitrile,

3-[5-(3-Pyridin-4-yl-4,5,6,7-tetrahydro-1,2,3a,8-tetraaza-azulen-8-ylmethyl)-tetrazol-2-yl]-benzonitrile,

3-{5-[1-(3-Pyridin-4-yl-4,5,6,7-tetrahydro-1,2,3a,8-tetraaza-azulen-8-yl)-ethyl]-tetrazol-2-yl}-benzonitrile,

(R) & (S)-4-(5-{1-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine,

2-(3-chloro-phenyl)-5-[(triphenyl- $\square^5$ -phosphanyl)-methyl]-2H-tetrazole hydrobromide,

4-(5-{2-[2-(3-chloro-phenyl)-2H-tetrazol-5-yl]-vinyl}-4-ethyl-4H-[1,2,4]triazol-3-yl)-pyridine,

4-(5-{2-[2-(3-chloro-phenyl)-2H-tetrazol-5-yl]-vinyl}-4-ethyl-4H-[1,2,4]triazol-3-yl)-  
pyridine,

1-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-2-(4-cyclopropyl-5-pyridin-4-yl-4H-[1,2,4]triazol-  
3-yl)-ethanol,

2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-1-(4-cyclopropyl-5-pyridin-4-yl-4H-[1,2,4]triazol-  
3-yl)-ethanol,

4-(5-{2-[2-(3-chloro-phenyl)-2H-tetrazol-5-yl]-vinyl}-4-ethyl-4H-[1,2,4]triazol-3-yl)-  
pyridine,

3-[4-Methyl-5-({[2-(3-methylphenyl)-2H-tetrazol-5-yl]methyl}thio)-4H-1,2,4-triazol-3-  
yl]benzonitrile,

5-({[5-(3,5-Difluorophenyl)-4-ethyl-4H-1,2,4-triazol-3-yl]thio}methyl)-2-(3-methylphenyl)-  
2H-tetrazole,

3-[4-Methyl-5-({1-[2-(3-methylphenyl)-2H-tetrazol-5-yl]ethyl}thio)-4H-1,2,4-triazol-3-  
yl]benzonitrile,

5-(1-{[5-(3,5-Difluorophenyl)-4-ethyl-4H-1,2,4-triazol-3-yl]thio}ethyl)-2-(3-methylphenyl)-  
2H-tetrazole,

6-(4-{1-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]ethyl}piperazin-1-yl)nicotinonitrile,  
3-(4-{1-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]ethyl}piperazin-1-yl)pyrazine-2-carbonitrile,  
2-(4-{1-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]ethyl}piperazin-1-yl)nicotinonitrile,  
1-{1-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]ethyl}-4-(3-nitropyridin-2-yl)piperazine,  
8-{1-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]ethyl}-3-(3,5-difluorophenyl)-5,6,7,8-  
tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine,  
8-{1-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]ethyl}-3-(4-methoxyphenyl)-5,6,7,8-  
tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine,  
3-(2-Chloro-6-methoxypyridin-4-yl)-8-{1-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]ethyl}-  
5,6,7,8-Tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine,  
8-{1-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]ethyl}-3-(2-methoxypyridin-4-yl)-5,6,7,8-  
tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine,  
8-{[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]methyl}-3-(2-methoxypyridin-4-yl)-5,6,7,8-  
tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine,  
3-(5-{[3-(2-Methoxypyridin-4-yl)-6,7-dihydro[1,2,4]triazolo[4,3-a]pyrimidine-8(5H)-  
yl]methyl}-2H-tetrazol-2-yl)benzonitrile,  
3-(2-Methoxypyridin-4-yl)-8-{1-[2-(3-iodophenyl)-2H-tetrazol-5-yl]ethyl}-5,6,7,8-  
tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine,

3-(5-{1-[3-(2-Methoxypyridin-4-yl)-6,7-dihydro[1,2,4]triazolo[4,3-a]pyrimidin-8(5H)-yl]ethyl}-2H-tetrazol-2-yl)benzonitrile,

3-(5-{[3-(2-Methoxypyridin-4-yl)-5,6,7,8-tetrahydro-9H-[1,2,4]triazolo[4,3-a][1,3]diazepin-9-yl]methyl}-2H-tetrazol-2-yl)benzonitrile,

3-(5-{[3-(2,6-Dimethoxypyrimidin-4-yl)-6,7-dihydro[1,2,4]triazolo[4,3-a]pyrimidin-8(5H)-yl]methyl}-2H-tetrazol-2-yl)benzonitrile,

(R) 3-(5-{1-[3-(2-Methoxypyridin-4-yl)-6,7-dihydro[1,2,4]triazolo[4,3-a]pyrimidin-8(5H)-yl]ethyl}-2H-tetrazol-2-yl)benzonitrile,

(S) 3-(5-{1-[3-(2-Methoxypyridin-4-yl)-6,7-dihydro[1,2,4]triazolo[4,3-a]pyrimidin-8(5H)-yl]ethyl}-2H-tetrazol-2-yl)benzonitrile,

(R) Ethyl 4-{1-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]ethyl}piperazine-1-carboxylate,

(S) Ethyl 4-{1-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]ethyl}piperazine-1-carboxylate,

(R) Ethyl 4-{1-[2-(5-chloro-2-fluorophenyl)-2H-tetrazol-5-yl]ethyl}piperazine-1-carboxylate,

(S) Ethyl 4-{1-[2-(5-chloro-2-fluorophenyl)-2H-tetrazol-5-yl]ethyl}piperazine-1-carboxylate,

(R) 6-(4-{1-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]ethyl}piperazin-1-yl)nicotinonitrile,

(S) 6-(4-{1-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]ethyl}piperazin-1-yl)nicotinonitrile,

(R) 3-(4-{1-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]ethyl}piperazin-1-yl)pyrazine-2-carbonitrile,



(S) 3-(4-{1-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]ethyl}piperazin-1-yl)pyrazine-2-carbonitrile,  
4-(5-{{(S)-1-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-ethoxy}-4-methyl-4H-[1,2,4]triazol-3-yl)-pyridine,  
2-(3-Chloro-phenyl)-5-{{(R)-1-[5-(3,5-difluoro-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yloxy]-ethyl}-2H-tetrazole,  
3-(5-{{(R)-1-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-ethoxy}-4-methyl-4H-[1,2,4]triazol-3-yl)-pyridine,  
4-(5-{2-[5-(3-Chlorophenyl)-2H-tetrazol-2-yl]propyl}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine,  
4-(5-{{(R)-1-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-ethoxy}-4-methyl-4H-[1,2,4]triazol-3-yl)-pyridine,  
2-(3-chlorophenyl)-5-[1-methyl-2-phenylvinyl]-2H-tetrazole, and  
2-({1-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]ethyl}thio)-imidazo[4,5-b]pyridine.

18. (Original) A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound according to any one of claims 1 to 17, in association with one or more pharmaceutically acceptable diluents, excipients and/or inert carriers.

19. (CANCELLED)

20. (Currently Amended) The compound according to ~~any one of claims 1 to 17~~ claim 1, for use in therapy.

21. (Currently Amended) The compound according to ~~any one of claims 1 to 17~~ claim 1, for use in treatment of mGluR 5 mediated disorders.

22. (Currently Amended) Use of the compound according to ~~any one of claims 1 to 17~~ claim 1, in the manufacture of a medicament for the treatment of mGluR 5 mediated disorders.

23. (Currently Amended) A method of treatment of mGluR 5 mediated disorders, comprising administering to a mammal, including man in need of such treatment, a therapeutically effective amount of the compound according to ~~any one of claims 1 to 17~~ claim 1.

24. (Original) The method according to claim 23, for use in treatment of neurological disorders.

25. (Original) The method according to claim 23, for use in treatment of psychiatric disorders.

26. (Original) The method according to claim 23, for use in treatment of chronic and acute pain disorders.

27. (Original) The method according to claim 23, for use in treatment of gastrointestinal disorders.

28. (Currently Amended) A method for inhibiting activation of mGluR 5 receptors, comprising treating a cell containing said receptor with an effective amount of the compound according to claim 1-17.